BIO-TECHNE CORPORATION (NASDAQ:TECH) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
A copy of the press release issued by Bio-Techne Corporation on February 5, 2019, describing the results of operations for the quarter ended December 31, 2018 and its financial condition as of December 31, 2018, is attached hereto as Exhibit 99.1.
The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events
A copy of the press release issued by Bio-Techne Corporation on February 5, 2019, announcing a cash dividend is attached hereto as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
BIO-TECHNE Corp Exhibit
EX-99.1 2 ex_133993.htm EXHIBIT 99.1 ex_133993.htm Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2019 RESULTS Minneapolis/February 5,…
To view the full exhibit click
About BIO-TECHNE CORPORATION (NASDAQ:TECH)
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.